{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:20Z","timestamp":1791005780294,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T00:00:00Z","timestamp":1318204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2288-11-139","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T02:25:16Z","timestamp":1318299916000},"source":"Crossref","is-referenced-by-count":292,"title":["Improved curve fits to summary survival data: application to economic evaluation of health technologies"],"prefix":"10.1186","volume":"11","author":[{"given":"Martin W","family":"Hoyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Henley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,10]]},"reference":[{"key":"650_CR1","volume-title":"Submission to NICE as part of STA program","author":"M Hoyle","year":"2008","unstructured":"Hoyle M, Rogers G, Garside R, Moxham T, Stein K: The clinical- and cost effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. Submission to NICE as part of STA program. 2008"},{"key":"650_CR2","volume-title":"Health Technology Assessment","author":"J Thompson-Coon","year":"2010","unstructured":"Thompson-Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K: Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment. 2010, 14:"},{"key":"650_CR3","volume-title":"Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)","author":"NICE","year":"2010","unstructured":"NICE: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line). 2010, [ http:\/\/guidance.nice.org.uk\/TA\/Wave17\/8 ]"},{"key":"650_CR4","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K: Decision modelling for health economic evaluation. 2006, Oxford, UK.: Oxford University Press"},{"key":"650_CR5","volume-title":"Modelling Survival Data in Medical Research","author":"D Collett","year":"2003","unstructured":"Collett D: Modelling Survival Data in Medical Research. 2003, Boca Raton: Chapman & Hall\/CRC, 2","edition":"2"},{"key":"650_CR6","volume-title":"Health Technology Assessment","author":"G Rogers","year":"2011","unstructured":"Rogers G, Hoyle M, Thompson-Coon J, Pitt M, Moxham T, liu Z, Stein K: Dasatinib and Nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: A systematic review and economic evaluation. Health Technology Assessment. 2011,"},{"key":"650_CR7","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.ejca.2006.08.010","volume":"42","author":"P Tappenden","year":"2006","unstructured":"Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S: Methodological issues in the economic analysis of cancer treatments. European Journal of Cancer. 2006, 42: 2867-2875. 10.1016\/j.ejca.2006.08.010.","journal-title":"European Journal of Cancer"},{"key":"650_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG: Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002, 359: 1686-1689. 10.1016\/S0140-6736(02)08594-X.","journal-title":"Lancet"},{"key":"650_CR9","volume-title":"Practical Statistics for Medical Research","author":"D Altman","year":"1991","unstructured":"Altman D: Practical Statistics for Medical Research. 1991, London, UK: Chapman & Hall\/CRC"},{"key":"650_CR10","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MKB Parmar","year":"1998","unstructured":"Parmar MKB, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine. 1998, 17: 2815-2834. 10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.","journal-title":"Statistics in Medicine"},{"key":"650_CR11","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1002\/sim.1303","volume":"21","author":"PR Williamson","year":"2002","unstructured":"Williamson PR, Smith CT, Hutton JL, Marson AG: Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine. 2002, 21: 3337-3351. 10.1002\/sim.1303.","journal-title":"Statistics in Medicine"},{"key":"650_CR12","volume-title":"Trials","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007, 8:"},{"key":"650_CR13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","volume":"5","author":"R Ihaka","year":"1996","unstructured":"Ihaka R, Gentleman R: R: A language for data analysis and graphics. J Comp Graph Stat. 1996, 5: 299-314. 10.2307\/1390807.","journal-title":"J Comp Graph Stat"},{"key":"650_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007, 356: 115-124. 10.1056\/NEJMoa065044.","journal-title":"New England Journal of Medicine"},{"key":"650_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/00949650215729","volume":"73","author":"ZL Yang","year":"2003","unstructured":"Yang ZL, Xie M: Efficient estimation of the Weibull shape parameter based on a modified profile likelihood. J Stat Comp Sim. 2003, 73: 115-123. 10.1080\/00949650215729.","journal-title":"J Stat Comp Sim"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2288-11-139\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-11-139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-11-139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-11-139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T14:05:28Z","timestamp":1741788328000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/1471-2288-11-139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1186\/1471-2288-11-139","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,10]]},"article-number":"139"}}